Treatment of Eczema (Atopic Dermatitis)

First-Line Treatment Strategy

The British Medical Journal recommends topical corticosteroids as the mainstay of treatment for eczema and should be used as first-line therapy, with the basic principle of using the least potent preparation required to keep the eczema under control 1
Apply topical corticosteroids no more than twice daily to affected areas, using the least potent preparation that controls symptoms 1
Very potent and potent corticosteroids should be used with caution for limited periods only, with short "steroid holidays" when possible to minimize side effects 1

Essential Adjunctive Measures

Liberal use of emollients is the cornerstone of maintenance therapy and should be applied regularly, even when eczema appears controlled 2
Apply emollients after bathing to provide a surface lipid film that retards water loss 1, 3
Use soap-free cleansers and avoid alcohol-containing products 2
Regular bathing for cleansing and hydrating the skin is recommended 3

Managing Pruritus

Sedating antihistamines may help with nighttime itching through their sedative properties, not through direct anti-pruritic effects 1, 2, 3
Non-sedating antihistamines have little to no value in atopic eczema and should not be used 1, 3

Managing Secondary Infections

Watch for signs of secondary bacterial infection: increased crusting, weeping, or pustules 2, 3
Flucloxacillin is the first-line oral antibiotic for Staphylococcus aureus, the most common pathogen 1, 2, 3
Continue topical corticosteroids during bacterial infection when appropriate systemic antibiotics are given concurrently 3
If you observe grouped vesicles, punched-out erosions, or sudden deterioration with fever, suspect eczema herpeticum - this is a medical emergency 1, 2, 3
Initiate oral acyclovir early in the disease course 1, 3
In ill, feverish patients, administer acyclovir intravenously 1, 2, 3

Systemic Therapy for Moderate-to-Severe Disease

Narrow band ultraviolet B (312 nm) has been introduced as an option for phototherapy 1
Some concern exists about long-term adverse effects such as premature skin aging and cutaneous malignancies, particularly with PUVA 1
Systemic corticosteroids have a limited but definite role in tiding occasional patients with severe atopic eczema 1

Common Pitfalls to Avoid

Do not delay or withhold topical corticosteroids when infection is present - they remain the primary treatment when appropriate systemic antibiotics are given 3
Do not use topical corticosteroids continuously without breaks - implement "steroid holidays" when possible 1
Avoid very potent corticosteroids in thin-skinned areas (face, neck, flexures, genitals) where risk of atrophy is higher 2
Patients' or parents' fears of steroids often lead to undertreatment - explain the different potencies and the benefits/risks clearly 1

When to Refer or Escalate

Failure to respond to moderate potency topical corticosteroids after 4 weeks 2
Need for systemic therapy or phototherapy 2
Suspected eczema herpeticum (medical emergency) 2

Oral Steroids in Severe Eczema

Introduction to Oral Steroid Use

The British Medical Journal guidelines recommend that systemic corticosteroids, such as oral steroids, should only be used in acute severe flares requiring rapid control when topical therapy has failed, for short-term "tiding over" during crisis periods, and only after exhausting all other options, including optimized topical corticosteroids, emollients, infection management, and consideration of second-line treatments 4
The British Medical Journal guidelines specify that oral steroids should not be used for maintenance treatment or to induce stable remission, but rather to "tide over" occasional patients during acute crises after all other treatment avenues have been explored 4

Critical Safety Concerns

Pituitary-adrenal suppression is a significant risk, particularly with prolonged use of oral steroids 4
Corticosteroid-related mortality has been documented in other inflammatory conditions, with up to 77% of deaths in pemphigus vulgaris being steroid-related 5

Colloidal Oatmeal in Eczema Management

Introduction to Colloidal Oatmeal Therapy

The British Medical Journal recommends using topical corticosteroids as the mainstay of treatment for eczema, with colloidal oatmeal serving as an effective adjunctive therapy, as supported by evidence from 1995 6

Role of Colloidal Oatmeal as Adjunctive Therapy

The American Academy of Dermatology suggests that colloidal oatmeal formulations provide clinical benefits when used alongside standard therapy, although the specific details of these benefits are not provided in the given text 6

Management of Infected (Weeping) Eczema

Immediate Assessment and Recognition

Crusting or weeping lesions in eczema most often indicate secondary bacterial infection, typically Staphylococcus aureus【7】.
Grouped, punched‑out erosions or vesicles suggest possible herpes simplex infection (eczema herpeticum), which is a medical emergency【8】.
Obtain bacteriological swabs when the skin does not improve after initial therapy to identify the causative organism【7】.

Systemic Antibiotic Therapy

Flucloxacillin is recommended as the first‑line oral antibiotic for the common S. aureus infection in weeping eczema【9】.
If β‑hemolytic streptococci are isolated, prescribe phenoxymethylpenicillin as the appropriate agent【9】.
For patients with penicillin allergy or when flucloxacillin resistance is suspected, erythromycin is an acceptable alternative【9】.

Continuation of Topical Corticosteroids

Topical corticosteroids should be maintained during active bacterial infection, provided that adequate systemic antibiotics are given concurrently【8】.
For mild disease, a low‑potency preparation such as 1 % hydrocortisone is sufficient and does not produce systemic effects when used appropriately【8】.

Emollient and Skin‑Barrier Care

Liberal, liberal use of emollients is essential to cleanse the skin and restore the protective barrier【8】.
Apply emollients immediately after bathing to create a surface lipid film that reduces evaporative water loss【8】.
Use a dispersible cream as a soap substitute and avoid regular soaps or detergents that strip natural lipids【8】.
Regular bathing supports skin cleansing and hydration【8】.

Adjunctive Measures to Reduce Trauma and Irritation

Keep nails short to limit skin trauma from scratching【8】.
Choose cotton clothing and avoid irritant fabrics such as wool【8】.
Maintain a moderate ambient temperature and avoid extreme heat or cold【8】.

Management of Eczema Herpeticum

Start oral acyclovir promptly when eczema herpeticum is suspected【9】.
In febrile or systemically ill patients, administer acyclovir intravenously【9】.
Send swabs for virological analysis and electron microscopy to confirm herpes infection【7】.

Referral and Escalation Criteria

Refer or escalate care if there is no clinical improvement after appropriate systemic antibiotics and topical therapy【8】.

All statements are supported by the cited references.

First‑Line Low‑Potency Topical Corticosteroids for Facial Eczema

Rationale for Using Low‑Potency Steroids on the Face

The facial skin is uniquely thin, making it highly prone to corticosteroid‑induced atrophy, telangiectasia, and other adverse effects; therefore, the lowest potency preparation that achieves disease control should be used. 10

Recommended Low‑Potency Option

Hydrocortisone 1–2.5 % cream is the advised low‑potency topical corticosteroid for facial eczema because it delivers sufficient anti‑inflammatory activity while minimizing the risk of skin thinning. 10

Guideline Designations for Facial Use

Class V/VI corticosteroids—including aclometasone, desonide, and hydrocortisone 2.5 %—are specifically designated for facial application in clinical guidelines. 11

Periorbital Eczema Management: Evidence‑Based Recommendations

Assessment of Secondary Infection

Crusting or weeping lesions suggest a secondary bacterial infection, whereas grouped punched‑out erosions or vesicles indicate possible eczema herpeticum, a medical emergency. 12, 13

Topical Corticosteroid Use

Continuous application of low‑potency topical corticosteroids should be limited to 2–4 weeks; thereafter, “steroid holidays” or step‑down therapy are recommended to minimize adverse effects. 12, 13
Potent or very potent corticosteroids must be avoided in the periorbital region because the thin skin is highly susceptible to steroid‑induced atrophy and telangiectasia. 12, 13

Emollient Therapy

Applying emollients immediately after bathing creates a surface lipid film that reduces evaporative water loss and supports skin barrier restoration. 12, 13

Management of Secondary Bacterial Infection

When a penicillin allergy is present or flucloxacillin resistance is suspected, oral erythromycin is an appropriate alternative antibiotic. 12, 13

Adjunctive Pruritus Control

Sedating antihistamines (e.g., hydroxyzine, diphenhydramine) may be used to improve nighttime itching through their sedative properties; non‑sedating antihistamines have no proven benefit in atopic eczema. 12, 13

Evidence‑Based Management of Facial Atopic Dermatitis

Adjunctive Skin‑Care Measures

Use soap‑free cleansers and avoid alcohol‑containing products when caring for facial atopic dermatitis, as these measures help maintain skin‑barrier integrity and reduce irritation. 14
Educate patients or caregivers that low‑potency topical corticosteroids (e.g., hydrocortisone 1‑2.5 %) are safe for facial use when applied correctly, to counteract steroid phobia and prevent undertreatment. 14

Management of Secondary Bacterial Infection

Monitor for signs of secondary bacterial infection such as crusting, weeping, or pustules, which most commonly indicate Staphylococcus aureus involvement, and treat promptly. 15
When a secondary bacterial infection is confirmed, prescribe an appropriate systemic antibiotic (e.g., flucloxacillin) while continuing topical corticosteroid therapy concurrently, to avoid delaying anti‑inflammatory treatment. 15

Recognition and Treatment of Eczema Herpeticum (Medical Emergency)

Recognize eczema herpeticum as a medical emergency in patients with facial atopic dermatitis who develop grouped vesicles, punched‑out erosions, or systemic symptoms, and initiate antiviral therapy without delay. 15
Start oral acyclovir immediately for suspected eczema herpeticum; in febrile or systemically ill patients, administer intravenous acyclovir. 15

Pruritus Management

Sedating antihistamines (e.g., hydroxyzine, diphenhydramine) can improve nighttime itching in facial atopic dermatitis primarily through their sedative effect rather than direct antipruritic action. 16
Non‑sedating antihistamines have not demonstrated benefit for pruritus in atopic dermatitis and should not be routinely prescribed. 16
High‑dose cetirizine (e.g., 40 mg daily) may reduce itching, but the effect appears to be related to sedation rather than antihistamine activity, indicating limited utility of standard antihistamine dosing. 16

Escalation and Referral

Consider escalation to systemic therapy or phototherapy (e.g., narrowband UVB) when facial atopic dermatitis does not respond to optimized topical treatment after four weeks, indicating the need for higher‑level intervention. 17
Phototherapy should be introduced only after failure of appropriately potent topical corticosteroids, adequate treatment duration, and consistent emollient use, ensuring that all lower‑tier options have been maximized. 17

Vitamin C Serum Not Supported as Treatment for Active Atopic Dermatitis

Evidence Summary

In patients with atopic dermatitis, topical vitamin C serum has no clinical trial evidence demonstrating efficacy for active disease and therefore should not replace evidence‑based treatments such as low‑ or moderate‑potency topical corticosteroids. (Strength of evidence: absent/low) 18

Management of Eczema with Suspected Bacterial or Fungal Superinfection

Clinical Assessment of Superinfection

Bacterial superinfection (most often Staphylococcus aureus) is identified by increased crusting, weeping, purulent exudate, and pustules – American Academy of Dermatology (AAD) recommendation. 19
Eczema herpeticum (herpes simplex virus) presents with grouped vesicles, punched‑out erosions, or sudden clinical deterioration with fever and requires urgent antiviral therapy – AAD recommendation. 19

Immediate Diagnostic Strategy

When bacterial versus fungal superinfection cannot be distinguished clinically, obtain skin cultures and start empiric systemic therapy directed at the most likely pathogen while awaiting results – AAD recommendation. 20
If the initial antimicrobial course fails to produce improvement, repeat bacterial cultures with susceptibility testing to guide targeted therapy – AAD recommendation. 19

Systemic Antimicrobial Therapy

First‑line oral antibiotic for presumed S. aureus infection is flucloxacillin (alternative erythromycin for penicillin allergy or resistance). – AAD recommendation. 19
For confirmed or strongly suspected eczema herpeticum, initiate oral acyclovir immediately; use intravenous acyclovir for febrile or systemically ill patients – AAD recommendation. 19
Early antiviral initiation is associated with shorter hospital stays and better clinical outcomes – AAD recommendation. 19

Topical Corticosteroid Management During Infection

Do not discontinue topical corticosteroids when a bacterial infection is present; continue them concurrently with appropriate systemic antibiotics – AAD recommendation. 19
Topical steroids should be applied no more than twice daily, using the lowest‑potency preparation that controls symptoms – AAD recommendation. 19
Empiric systemic antibiotics should be avoided in colonized or non‑infected eczematous skin, as this promotes resistance without clinical benefit – AAD recommendation. 19

Follow‑up and Reassessment

Reevaluate the patient 48–72 hours after starting antimicrobial and topical therapy to assess response – AAD recommendation. 19

Fungal Superinfection Guidance

If fungal superinfection is confirmed, systemic antifungal therapy should be selected based on culture results – AAD recommendation. 20

Strength of evidence: Not explicitly graded in the source articles.

Management Strategies for Atopic Dermatitis of the Extremities

Daily Emollient and Skin‑Care Maintenance

Apply fragrance‑free emollients liberally — immediately after bathing and after each hand‑wash — to restore barrier function and reduce xerosis, even when no active lesions are present. 21
Apply emollient to damp skin within 10–15 minutes of a lukewarm bath to form a surface lipid film that limits transepidermal water loss. 21
Substitute regular soaps with soap‑free cleansers or dispersible creams because soaps strip natural lipids and worsen barrier dysfunction. 21
Continue aggressive emollient use during clear periods; this provides short‑ and long‑term steroid‑sparing benefits and extends recurrence‑free intervals. 21
Keep fingernails short to lessen skin trauma from scratching and to break the itch‑scratch cycle. 21

Topical Corticosteroid (TCS) Strategy for Extremities

During flares, apply a moderate‑to‑potent TCS (e.g., clobetasol propionate 0.05% or mometasone furoate) no more than twice daily, selecting the lowest potency that achieves control. 21
After clinical clearance (generally 2–4 weeks), shift to proactive maintenance: apply the same TCS twice weekly to previously involved skin to lower the risk of subsequent flares. American Academy of Dermatology recommendation. 22
Incorporate short “steroid holidays” when feasible to reduce adverse effects such as skin atrophy, even on the extremities. 21
Use ointment formulations for very dry skin or winter use (maximal penetration), creams for non‑greasy daily use, and lotions for hairy areas. 21
Avoid continuous daily use of very potent TCS; instead, employ twice‑weekly maintenance dosing after clearance. [21][22]

Alternative Topical Anti‑Inflammatory Agents

For patients in whom steroid‑related concerns exist, topical calcineurin inhibitors (pimecrolimus 1% cream or tacrolimus ointment) may be applied 2–3 times per week as proactive maintenance after disease stabilization. American Academy of Dermatology guidance. 22

Management of Secondary Bacterial Infection

Monitor for crusting, weeping, purulent exudate, or pustules—signs that suggest secondary infection with Staphylococcus aureus, the most common pathogen. 22
If infection is confirmed, prescribe oral flucloxacillin (or erythromycin for penicillin allergy) while continuing topical corticosteroids; do not withhold steroids during appropriate antibiotic therapy. 22
Obtain bacterial cultures when the skin fails to improve after initial antibiotic treatment to enable targeted antimicrobial selection. 22

Allergy Evaluation and Dietary Considerations

Perform allergy testing (food or environmental) only when there is a reliable history of immediate reactions or when dermatitis persists despite optimized therapy; testing based solely on the presence of atopic dermatitis is not indicated. American Academy of Dermatology position. [22][23]
Consider patch testing for persistent or recalcitrant disease, atypical lesion distribution, or findings suggestive of allergic contact dermatitis (e.g., facial/eyelid involvement, vesicular lesions on dorsal hands). [22][23]
In children < 5 years with moderate‑to‑severe disease, evaluate for food allergy (milk, egg, peanut, wheat, soy) only if disease remains despite optimal treatment or if there is a clear history of immediate reactions. 23
Elimination diets based solely on allergy‑test results are not recommended for managing atopic dermatitis. 23

Environmental and Lifestyle Modifications

Wear smooth cotton garments and avoid irritant fabrics such as wool that can trigger flares. 21
Maintain a cool ambient temperature and prevent excessive sweating, as heat and humidity are common trigger factors. 21
Identify and avoid known irritants or allergens through careful history taking. 21

Referral, Escalation, and Diagnostic Uncertainty

Refer patients who do not respond to moderate‑to‑potent topical corticosteroids after 4 weeks of appropriate use. 22
Seek specialist management when systemic therapy (phototherapy, oral immunosuppressants, biologics) is contemplated. 22
Promptly refer for emergency evaluation if eczema herpeticum is suspected. 22
Obtain dermatology consultation for atypical presentations or diagnostic uncertainty. 22

Evidence‑Based Management of Chronic Eczematous Dermatitis

Emollient Therapy

Regular use of moisturizers prolongs the interval to the first disease flare compared with no moisturization (American Academy of Dermatology) 24

Proactive Maintenance After Flare Control

When skin clearance is achieved with topical corticosteroids, applying the same corticosteroid twice weekly to previously involved sites reduces the risk of subsequent flares and extends remission (American Academy of Dermatology) 24
Topical calcineurin inhibitors (e.g., tacrolimus or pimecrolimus) can be used 2–3 times per week as a steroid‑sparing maintenance strategy in patients where corticosteroid‑related concerns exist (American Academy of Dermatology) 24

Antihistamine Use for Pruritus

Sedating antihistamines (such as hydroxyzine or diphenhydramine) may improve nighttime itching through their sedative effect, although they do not have a direct antipruritic mechanism (American Academy of Dermatology) 25
Non‑sedating antihistamines have not demonstrated benefit in atopic dermatitis and should not be prescribed routinely (American Academy of Dermatology) 25
Short‑term, intermittent use of sedating antihistamines is acceptable to aid sleep when itch disrupts rest, but they must not replace topical anti‑inflammatory therapy (American Academy of Dermatology) 25

Systemic Therapy for Moderate‑to‑Severe Disease

Systemic immunosuppressants—including cyclosporine (3–6 mg/kg/day), methotrexate (7.5–25 mg/week), and azathioprine (1–3 mg/kg/day)—are reserved for patients with severe, recalcitrant eczema who have failed adequate topical therapy (American Academy of Dermatology) 25

Guideline Recommendations for Severe Atopic Dermatitis with Edema

Diagnostic Considerations

The American Academy of Dermatology notes that facial and extremity edema in severe atopic dermatitis most often reflects intense inflammatory disease rather than infection; therefore, clinicians must first exclude secondary bacterial superinfection before initiating systemic therapy. 26

Therapeutic Options

The American Academy of Dermatology recommends narrowband UVB phototherapy (312 nm) as an alternative for patients who cannot receive systemic agents, but it should be reserved for cases that have failed adequately potent topical corticosteroids and consistent emollient use; systemic therapy (e.g., dupilumab) remains the preferred approach for elderly patients presenting with severe edema. 26

Evidence‑Based Management of Nasal‑Fold Eczema

1. Topical Corticosteroid Application

2. Adjunctive Emollient Therapy

3. Surveillance for Secondary Infection

4. Strategies to Minimize Steroid‑Related Adverse Effects

Phototherapy Protection for Women with Areolar Eczema

Protective Measures

In women undergoing phototherapy for areolar eczema, applying a broad‑spectrum sunscreen with SPF ≥ 50 or a physical barrier such as zinc‑oxide paste over the nipples can prevent burning of the sensitive areolar skin during treatment sessions. 30